



REGD. OFFICE : 534, SARDAR VALLABHBHAI PATEL ROAD, MUMBAI - 400 007. PHONE : 23612195
CIN : L74999MH1919PLC000557, E-mail : bcma@bcma.in, Website : www.bcma.in

BCMA: SEC: 2026
August 10, 2026

BSE Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Fax: 22723121/2039/2037
BSE Scrip Code - 501430

Dear Sir(s),

Re.: Published copy of Unaudited Standalone and Consolidated Financial Results for the Quarter Ended June 30, 2026 as per Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Further to our submission as per Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, of the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended on June 30, 2026, we enclose copies of newspaper cutting of Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2026, published on Saturday, August 08, 2026, in The Financial Express in all Editions and Mumbai Lakshdeep.

Please take the same on your record.

Thanking you,

Yours faithfully,
For Bombay Cycle & Motor Agency Ltd.

Nidhi Agarwal
Company Secretary & Compliance Officer
Encl.: as above

FORM A
PUBLIC ANNOUNCEMENT
(Under Regulation 6 of the Insolvency and Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)
FOR THE ATTENTION OF THE CREDITORS OF
MATOSHREE INFRASTRUCTURE PRIVATE LIMITED.

RELEVANT PARTICULARS

1	Name of Corporate Debtor (CD)	MATOSHREE INFRASTRUCTURE PRIVATE LIMITED
2	Date of incorporation of corporate debtor	24/08/2007
3	Authority under which corporate debtor is incorporated/registered	Registrar of Companies – Mumbai
4	Corporate Identity No. of corporate debtor	U45203MH2007PTC173437
5	Address of the registered office and principal office (if any) of corporate debtor	Regd Address: 102-Aditi, Sanabhavan Path, Dadar (West), Mumbai, Maharashtra, India - 400028.
6	Insolvency commencement date in respect of Corporate Debtor	05/08/2026
7	Estimated date of closure of insolvency resolution process	01/02/2027
8	Name and Registration Number of the insolvency professional acting as interim resolution professional	Name: Solvenza Advisory LLP (formerly known as SSARVI Resolution Services LLP) Through Its Authorized Signatory Shri. Prashant Jain Registration No. IBBI/PE-0144/PA-1/2022-23/50008
9	Address and e-mail of the Interim Resolution Professional, as registered with the Board	Regd Add: Office No. 1, First floor, Gami Tera, Plot No. 45-51, Sector 6, Sanpada, Navi Mumbai-400705 Email id: solvenza.ipe@gmail.com
10	Address and e-mail to be used for correspondence with the interim resolution professional	Solvenza Advisory LLP (formerly known as SSARVI Resolution Services LLP) Add: Office No. 1, First floor, Gami Tera, Plot No. 45-51, Sector 6, Sanpada, Navi Mumbai-400705 Email: crpmatoshreinfrastructure@gmail.com
11	Last date for submission of claims	19/08/2026
12	Classes of creditors, if any, under clause (b) of sub-section (6A) of section 21, ascertained by the interim resolution professional	Home Buyers
13	Names of Insolvency Professionals identified to act as Authorised Representative of creditors in a class (Three names for each class)	1. MR. NILESH KOTHARI IBBI Reg. No.: IBBI/PA-002/IP-N01225/2022/2023/14132 2. MR. RISHABH SETHI IBBI Reg. No.: IBBI/PA-001/IP-P-02842/2023-2024/14377 3. MR. VIVEK SATYAPRAKASH JALAN IBBI Reg. No.: IBBI/PA-002/IP-N01295/2024-2025/14452
14	(a) Relevant Forms and (b) Details of authorized representatives are available at	https://www.ibbi.gov.in/home/downloads NA

Notice is hereby given that the Hon'ble National Company Law Tribunal, Mumbai Bench has ordered the commencement of a Corporate Insolvency Resolution Process of **MATOSHREE INFRASTRUCTURE PRIVATE LIMITED** on 05/08/2026.

The creditors of **MATOSHREE INFRASTRUCTURE PRIVATE LIMITED** are hereby called upon to submit their claims with proof on or before 19/08/2026 to the interim resolution professional at the address mentioned against entry No. 10.

The financial creditors shall submit their claims with proof by electronic means only. All other creditors may submit the claims with proof in person, by post, or by electronic means.

Submission of false or misleading proofs of claim shall attract penalties.

Sd/-
Mr. Prashant Jain
Authorised Signatory of Solvenza Advisory LLP (Formerly known as SSARVI Resolution Services LLP)

Registration No.: IBBI/PE-0144/PA-1/2022-23/50008
Interim Resolution Professional in the matter of
MATOSHREE INFRASTRUCTURE PRIVATE LIMITED

Date: 08/08/2026
Place: Mumbai

EMERALD COMMERCIAL LIMITED				
Registered Office : 18, RABINDRA SARANI, PODDAR COURT, GATE NO 4, 4TH FLOOR, ROOM NO 4, KOLKATA-700001				
CIN : L29299WB1983PLC036040				
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026				
Sl. No.	PARTICULARS	Rs. (Lacs except EPS)		
		QUARTER ENDED		YEAR ENDED
		30-Jun-26 (Unaudited)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)
1	Revenue			
	Total Income	874.42	2,210.71	7,185.27
2	Expenses			
	Total expenses	861.50	2,199.70	7,160.74
3	Profit before Exceptional Items and Tax (1 - 2)	12.92	11.01	24.53
4	Exceptional Items	-	-	-
5	Profit Before Tax (3 - 4)	12.92	11.01	24.53
6	Tax Expense	3.36	2.86	6.38
7	Profit for the year (5-6)	9.56	8.15	18.15
8	Other Comprehensive Income (net of tax)			
9	Total Comprehensive Income for the year	9.56	8.15	18.15
10	Paid-up equity share capital (Face Value of the Share Rs.10/- each)	435,988,370	435,988,370	435,988,370
11	Earnings per share (of Rs. 10/- each) :			
	(a) Basic	0.022	0.019	0.042
	(b) Diluted	0.022	0.019	0.042

Note:
Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.

Sd/-
Indrajit Sett
Managing Director
DIN No. 03581182

Place: Kolkata
Date: 07/08/2026



BOMBAY

CYCLE & MOTOR

AGENCY LTD.

BOMBAY CYCLE & MOTOR AGENCY LIMITED

Regd Office: 534, Sardar Vallabhbhai Patel Road, Opera House, Mumbai - 400 007.

CIN : L74999MH1919PLC000557

Tel.:022-23612195 / 96 / 97, e-mail: bcma@bcma.in, website:www.bcma.in

IOL Chemicals and Pharmaceuticals Limited

CIN: L24116PB1986PLC007030

Regd Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala, 148107, Punjab (India)
Corporate Office: 85, Industrial Area 'A', Ludhiana-141003 (Punjab)
Tel: +91-161-4560500, E-mail: investor@iolcp.com, Website : www.iolcp.com

NOTICE OF THE 39TH ANNUAL GENERAL MEETING AND E-VOTING INFORMATION ETC.

NOTICE is hereby given that the 39th Annual General Meeting ("AGM") of the Members of IOL Chemicals and Pharmaceuticals Limited ("the Company") will be held on **Wednesday, 2nd September 2026 at 11:30 AM (IST)** through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the businesses as set out in the Notice of the AGM (the "AGM Notice") in compliance with all the applicable provisions of the Companies Act, 2013 ("the Act"), the Rules made thereunder and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with General Circular No. 3/2025 dated 22nd September 2025, issued by the Ministry of Corporate Affairs (MCA) and the circulars issued from time to time by SEBI (hereinafter collectively referred to as "the Circulars").

In compliance with the Circulars, the AGM Notice and Integrated Annual Report for the financial year 2025-26 have been sent on 7th August 2026 to the Members of the Company whose e-mail addresses are registered with the Company/Depository Participant(s). The requirement of sending the physical copy of the AGM Notice and Integrated Annual Report to the members has been dispensed with vide above said Circulars. The aforesaid documents are also available on the Company's website at www.iolcp.com and on the website of the Stock Exchanges i.e. BSE Limited ("BSE") and National Stock Exchange of India, Limited ("NSE") at www.bseindia.com and www.nseindia.com respectively. The AGM Notice is also available on the website of Central Depository Services (India) Limited ("CDSL") at www.evotingindia.com. The procedure for registration of email addresses by members whose email addresses are not registered with company / RTA / Depositories is provided in the AGM Notice.

Pursuant to the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of the Listing Regulations and Relevant Circulars, the Company is providing to all its members, the facility to exercise their right to vote through remote e-voting before and during the AGM in respect of businesses to be transacted at the AGM and for this purpose the Board of Directors of the Company has appointed CDSL to facilitate voting through electronic means. The right of voting can be exercised by all the Members, who hold shares on **26th August 2026 (Cut-off date)**, by using remote e-voting facility before or during the AGM on any or all the businesses set out in the AGM Notice. The detailed instructions for remote e-voting facility and e-voting during the AGM are forming part of the AGM Notice.

We would also like to inform all the members that:

- The Ordinary and Special Businesses, as set out in the AGM Notice, shall be transacted through voting by electronic means and there shall be no physical voting on any business.
- The **Cut-off date** for determining the eligibility to vote on any business items mentioned in AGM Notice is **26th August 2026**. A person whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date shall be entitled to avail the facility of remote e-voting as well as voting during the AGM.
- The remote e-Voting period shall commence on **30th August 2026 at 9:00 AM (IST) and end on 1st September 2026 at 5:00 PM (IST)**.
- The remote e-Voting module shall be disabled by CDSL after the aforesaid date and time. Once the vote on a resolution is cast by the member, the member cannot modify or change it subsequently.
- The members who have cast their vote by remote e-voting prior to the 39th AGM shall be allowed to participate in the AGM through VC/OAVM but shall not be entitled to cast their vote again during the AGM. However, the members participating in the AGM and who had not cast their vote through remote e-voting and are otherwise not barred from doing so, shall be entitled to cast their vote through e-voting system available during the AGM.
- Book Closure:** The Register of Members and Share Transfer Books will remain closed from **27th August 2026 to 2nd September 2026** for the purpose of the AGM.
- Detailed procedure for remote e-voting or e-voting during the AGM along with instructions for attending the AGM through VC/OAVM are provided in the AGM Notice.

Any person who becomes the member of the Company after sending the AGM Notice by email and holds shares as on **Cut-off date i.e. 26th August 2026** may obtain the login credentials by sending a request at helpdesk.evoting@cdslindia.com. However, if a person is already registered with CDSL for remote e-voting, he can use his existing Login ID and Password and cast his vote. The detailed process for obtaining Login ID and Password is provided in the AGM Notice.

For any query/clarification or issues regarding remote e-voting / e-voting during the AGM, you may refer the Frequently Asked Questions ("FAQs") and e-voting manual available at www.evotingindia.com, under help section or contact Mr. Rakesh Dalvi, Sr. Manager, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatol Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 21 099 11.

Sd/-
Abhay Raj Singh
Sr. Vice President & Company Secretary

Place : Ludhiana
Date: 7th August 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.

INITIAL PUBLIC OFFERING OF EQUITY SHARES OF AGS HEALTH LIMITED ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES" IN COMPLIANCE WITH CHAPTER II and IIA OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").



(Please scan this QR code to view the UDRHP-I and Draft Abridged Prospectus)

PUBLIC ANNOUNCEMENT



Our Company was originally incorporated as 'Adroit Global Solutions India Private Limited' at Chennai, Tamil Nadu as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 12, 2010, issued by the Registrar of Companies, Tamil Nadu and Andaman and Nicobar Islands, Chennai ("RoC"). Our Company changed its name to 'AGS Health Private Limited' pursuant to a resolution of our Shareholders on July 20, 2011 and a fresh certificate of incorporation dated August 30, 2011 was issued by the RoC. Subsequently, our Company was converted to a public limited company and the name of our Company changed to 'AGS Health Limited' pursuant to a Shareholders' resolution dated March 11, 2026 and a fresh certificate of incorporation dated March 17, 2026 was issued by the Registrar of Companies, Central Registration Centre. For details, see "History and Certain Corporate Matters - Brief history of our Company" on page 240 of the updated draft red herring prospectus - I dated August 7, 2026 ("UDRHP-I").

Registered and Corporate Office: 'B' Wing, 2nd Floor, Prince Infocity II, 141, Kottivakkam Village, Rajiv Gandhi Salai, Kandanchavadi, Chennai, Tamil Nadu, India – 600 096
Tel: +91 44 45104520; **Website:** www.agshealth.com; **Contact person:** Kothandaraman Prasad, Company Secretary and Compliance Officer
E-mail: investors@agshealth.com; **Corporate Identity Number:** U72200TN2010PLC078062

OUR PROMOTER: BCP ASIA II TOPCO VIII PTE. LTD.

INITIAL PUBLIC OFFERING OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH ("EQUITY SHARES") OF AGS HEALTH LIMITED (OUR "COMPANY" OR THE "COMPANY") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ 48,000 MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING UP TO ₹18,000 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING UP TO ₹ 30,000 MILLION (THE "OFFER FOR SALE") BY BCP ASIA II TOPCO VIII PTE. LTD. (THE "PROMOTER SELLING SHAREHOLDER" AND SUCH SHARES, THE "OFFERED SHARES"). FOR DETAILS OF THE PROMOTER SELLING SHAREHOLDER, SEE "THE OFFER" BEGINNING ON PAGE 73 OF THE UDRHP-I.

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A PRE-IPO PLACEMENT OF SPECIFIED SECURITIES AGGREGATING UP TO ₹ 3,600.00 MILLION, AS MAY BE PERMITTED UNDER APPLICABLE LAW, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND THE PROSPECTUS.

THE OFFER INCLUDES A RESERVATION OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH, AGGREGATING UP TO ₹ [•] MILLION (CONSTITUTING UP TO [•]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (AS DEFINED HEREINAFTER) ("EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". OUR COMPANY MAY, IN CONSULTATION WITH THE BRLMS, OFFER A DISCOUNT OF UP TO ₹ [•] OF THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT"). THE OFFER AND THE NET OFFER SHALL CONSTITUTE [•]% AND [•]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, RESPECTIVELY.

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of *force majeure*, banking strike or similar unforeseen circumstances, our Company in consultation with the BRLMs, may for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of one Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and intimation to SCSBs (as defined hereinafter), Designated Intermediaries (as defined hereinafter) and the Sponsor Banks (as defined hereinafter) as applicable.

This is an Offer in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. This Offer is being made through the Book Building Process in compliance with Regulation 6(2) of the SEBI ICDR Regulations wherein at least 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Bidders ("QIBs") and such portion the "QIB Portion" provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which up to 40% shall be reserved as under: (i) up to 33.33% for domestic Mutual Funds; and (ii) up to 6.67% shall be reserved for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to the Anchor Investors ("Anchor Investor Allocation Price"), in accordance with the SEBI ICDR Regulations. Any under-subscription in the reserved category specified in clause (ii) above, may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Net Offer cannot be Allotted to QIBs, then the entire Bid Amount (as defined hereinafter) will be refunded forthwith. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders ("NIBs") of which (a) one third portion shall be reserved for NIBs with application size of more than ₹ 0.20 million and up to ₹ 1.00 million; and (b) two-thirds of the portion shall be reserved for NIBs with application size of more than ₹ 1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to Bidders in the other sub-category of NIBs in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price and not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees Bidding under the Employee Reservation Portion, subject to valid Bids being received from them at or above the Offer Price (net of Employee Discount, if any). All Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID (in case of UPI Bidders using the BRLMs on or before 5.00 p.m. on the 21st day from the date of publication of this public announcement, in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "Offer Procedure" beginning on page 637 of the UDRHP-I.

This public announcement is being made in compliance with the provisions of Regulations 59C(9), 59C(9A) and 59C(10) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Offer and has filed the UDRHP-I and Draft Abridged Prospectus with SEBI and the Stock Exchanges on August 7, 2026. Pursuant to Regulation 59C(9), 59C(9A) and 59C(10) of the SEBI ICDR Regulations, the UDRHP-I and Draft Abridged Prospectus filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it on the website of SEBI at www.sebi.gov.in, website of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.agshealth.com and on the websites of the BRLMs, i.e. ICICI Securities Limited, Jefferies India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.icicisecurities.com, www.jefferies.com, www.jpmf.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Our Company hereby invites the public to give their comments on the UDRHP-I and the Draft Abridged Prospectus filed with SEBI and the Stock Exchanges, with respect to disclosures made in the UDRHP-I and the Draft Abridged Prospectus. The members of the public are requested to send a copy of the comments to SEBI and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs on or before 5.00 p.m. on the 21st day from the date of publication of this public announcement.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Updated Draft Red Herring Prospectus - I. Specific attention of the investors is invited to "Risk Factors" beginning on page 27 of the UDRHP-I.

Any decision to invest in the Equity Shares described in the UDRHP-I may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP. The Equity Shares, when offered through the RHP, are proposed to be listed on Stock Exchanges.

For details of the share capital and capital structure, the names of the signatories to the Memorandum of Association ("MOA") and the number of shares of our Company subscribed by them, please see the section titled "Capital Structure" on page 94 of the UDRHP-I. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in the MOA, please see the section titled "History and Certain Corporate Matters - Brief History of our Company" on page 240 of the UDRHP-I.

BOOK RUNNING LEAD MANAGERS TO THE OFFER					REGISTRAR TO THE OFFER
					
ICICI Securities Limited ICICI Venture House Appasaheb Marathe Marg, Prabhadevi Mumbai - 400 025, Maharashtra, India Tel: +91 22 6807 7100 E-mail: agshealth.ipo@icicisecurities.com Website: www.icicisecurities.com Investor Grievance Email: customercare@icicisecurities.com Contact Person: Shri Subramanyam / Namrata Ravasia SEBI Registration Number: INM000011179	Jefferies India Private Limited Level 16, Express Towers Nariman Point, Mumbai - 400 021 Maharashtra, India Tel: +91 22 4356 6000 E-mail: AGSHealth.IPO@jefferies.com Website: www.jefferies.com Investor Grievance Email: ijpl.grievance@jefferies.com Contact Person: Akshat Shah/ Asi Shah SEBI Registration Number: INM000011443	JM Financial Limited 7th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025 Maharashtra, India Tel: + 91 22 6630 3030 E-mail: agshealth.ipo@jmfml.com Website: www.jmfml.com Investor Grievance Email: grievance.lbd@jmfml.com Contact Person: Prachee Dhuri SEBI Registration Number: INM000010361	J.P. Morgan India Private Limited J.P. Morgan Tower, Off C.S.T. Road Kalina, Santacruz (East), Mumbai - 400 098, Maharashtra, India Tel: +91 22 6157 3000 E-mail: AGS_Health_IPO_2026@jpmorgan.com Website: www.jpmpit.com Investor Grievance Email: investorsmb.jpmpit@jpmorgan.com Contact Person: Darshil Mehta / Kritvsee Bastawala SEBI Registration Number: INM000002970	Nomura Financial Advisory and Securities (India) Private Limited Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018 Maharashtra, India Tel: +91 22 4037 4037 E-mail: agshealthipo@nomura.com Website: www.nomuraholdings.com/company/group/asia/india/index.html Investor Grievance Email: investorgrievances-in@nomura.com Contact Person: Vishal Kanjani / Yash Thakar SEBI Registration Number: INM000011419	MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) C-101, 247 Embassy West L B Marg, Vikhroli (West) Mumbai - 400 083, Maharashtra, India Tel: +91 810 811 4949 E-mail: agshealth.ipo.in.in.mprms.mufg.com Website: https://in.mprms.mufg.com/ Investor Grievance Email: agshealth.ipo.in.in.mprms.mufg.com Contact Person: Shanti GopalKrishnan SEBI Registration Number: INR000004058